In 2004, clinical development of CAT-354 was initiated with this first study completing in 2005. [16] On 21 July 2011, MedImmune LLC initiated a Phase IIb, randomized, double-blind study to evaluate the efficacy of tralokinumab in adults with asthma.

Here we describe the preclinical in vitro and in vivo characterization of CAT-354, an IL-13-neutralizing IgG4 monoclonal antibody (mAb), currently in clinical development. In vitro the potency, specificity and species selectivity of CAT-354 was assayed in TF-1 cells, human umbilical vein endothelial cells and HDLM-2 cells.

A Phase 3 Multi-center Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children (Age 2 to <12 Years) and Infants (Age 6 Months to <2 Years) With Moderate-to-severe Atopic Dermatitis.

2021年11月1日 · 2.3.3 CAT-354 (tralokinumab) Tralokinumab是阿斯利康(AstraZeneca) 公司研发的一种靶向IL-13的全人源单克隆抗体, 其Ⅱ期临床试验结果显示, 药物在毒副作用方面表现良好, 但对肺纤维化疗效不佳, 因此阿斯利康宣布终止tralokinumab在IPF领域的进一步研究 [ 15 ] 。

2011年9月6日 · CAT-354 is a highly potent and specific IL-13 neutralizing antibody with a 165 pM affinity for human IL-13 that neutralized human and cynomolgus IL-13 with near equivalent potency but did not neutralize mouse IL-13 nor the most homologous cytokine to …

In vivo CAT-354 was tested on human IL-13-induced air pouch inflammation in mice, ovalbumin-sensitization and challenge in IL-13 humanized mice and antigen challenge in cynomolgus monkeys. Key results: CAT-354 has a 165 pM affinity for human IL-13 and functionally neutralized human, human variant associated with asthma and atopy (R130Q) and ...

2012年4月25日 · Tralokinumab (CAT-354) 是一种人免疫球蛋白 G4 (IgG4) 抗 IL-13 单克隆抗体，已在临床前模型中显示出有效和特异性中和 IL-13。 本研究将评估单剂量的 PK 曲线将 tralokinumab 以 300 mg 的剂量皮下注射给患有哮喘的青少年受试者，并将其与来自已完成的成人研究的 PK 数据进行 ...

2019年11月1日 · Tralokinumab (CAT-354) is a fully humanized IgG 4 mAb, which specifically and effectively neutralizes IL-13 interaction with IL-13 receptor α1/2. 14, 15 Recently, several clinical studies have evaluated the efficacy and safety of tralokinumab (CAT-354) for the treatment of moderate to severe asthma. However, the reported efficacy of ...

In this case study, we describe the use of in vitro protein evolution with ribosome display to improve the potency of a human interleukin-13-neutralising antibody by a factor of over 200-fold and derive a therapeutic candidate, CAT-354, for the treatment of asthma.

医药魔方NextPharma®全球新药数据库为您提供「tralokinumab」药品的基本信息（药品名称、药品类别、靶点、作用机制、药品简介、研发机构、最高研发阶段、审评审批类型、外置链接）。 了解更多药品相关信息，欢迎申请试用企业版。